Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer

BACKGROUND: Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. Emerging real-life data suggest that the efficacy of a palbociclib-based therapy is highly conserved. We report the In...

Descripción completa

Detalles Bibliográficos
Autores principales: Porte, B., Carton, M., Lerebours, F., Brain, E., Loirat, D., Haroun, L., Bellesoeur, A., Bach Hamba, S., Kirova, Y., Cottu, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695984/
https://www.ncbi.nlm.nih.gov/pubmed/33242757
http://dx.doi.org/10.1016/j.breast.2020.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695984/
https://www.ncbi.nlm.nih.gov/pubmed/33242757
http://dx.doi.org/10.1016/j.breast.2020.11.008

Ejemplares similares